Cambridge Labs' Valtropin cleared in EU

14 May 2006

Cambridge Laboratories, a UK-based specialist pharmaceutical company, says that the European Medicines Agency's Committee on Medicinal Products for Human Use has granted European Union marketing authorization to its biosimilar medicinal product, Valtropin, a recombinant human growth hormone for the treatment of growth deficiency in children.

The agent was licensed from BioPartners, a privately-held Swiss drugmaker that owns the global rights to the product. BioPartners licensed the UK rights to Cambridge Labs, which plans to launch the agent in the current year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight